Login
Evidence Feed
About
Diagnostics
New
Top genes
FAQ
Contact us
^
Login
Home
>
Evidence Feed
VERI cancer hierarchy
Reset Filters
BRAF V600E
Glioma
BRAF V600E
Glioma
trametinib + dabrafenib
Sensitive: A1 - Approval
Novartis Press Release - 5 days (New A2)
trametinib + dabrafenib
Sensitive
:
A1
Novartis Press Release - 5d
trametinib + dabrafenib
Sensitive: A1 - Approval
Novartis Press Release - 5 days
trametinib + dabrafenib
Sensitive
:
A1
Novartis Press Release - 5 days - (New A2)
BRAF fusion
Glioma
BRAF fusion
Glioma
tovorafenib
Sensitive: A1 - Approval
BioSpace - 6 days (New A1)
tovorafenib
Sensitive
:
A1
BioSpace - 6d
tovorafenib
Sensitive: A1 - Approval
BioSpace - 6 days
tovorafenib
Sensitive
:
A1
BioSpace - 6 days - (New A1)
BRAF V600
Glioma
BRAF V600
Glioma
tovorafenib
Sensitive: A1 - Approval
BioSpace - 6 days (New A1)
tovorafenib
Sensitive
:
A1
BioSpace - 6d
tovorafenib
Sensitive: A1 - Approval
BioSpace - 6 days
tovorafenib
Sensitive
:
A1
BioSpace - 6 days - (New A1)
BRAF rearrangement
Glioma
BRAF rearrangement
Glioma
tovorafenib
Sensitive: A1 - Approval
BioSpace - 6 days (New A1)
tovorafenib
Sensitive
:
A1
BioSpace - 6d
tovorafenib
Sensitive: A1 - Approval
BioSpace - 6 days
tovorafenib
Sensitive
:
A1
BioSpace - 6 days - (New A1)
No biomarker
Multiple Myeloma
No biomarker
Multiple Myeloma
ciltacabtagene autoleucel
Sensitive: A1 - Approval
J&J Press Release - 1 week (New A1)
ciltacabtagene autoleucel
Sensitive
:
A1
J&J Press Release - 1wk
ciltacabtagene autoleucel
Sensitive: A1 - Approval
J&J Press Release - 1 week
ciltacabtagene autoleucel
Sensitive
:
A1
J&J Press Release - 1 week - (New A1)
ALK positive
Non Small Cell Lung Cancer
ALK positive
Non Small Cell Lung Cancer
alectinib
Sensitive: A1 - Approval
FDA - 1 week (New A1)
alectinib
Sensitive
:
A1
FDA - 1wk
alectinib
Sensitive: A1 - Approval
FDA - 1 week
alectinib
Sensitive
:
A1
FDA - 1 week - (New A1)
No biomarker
Squamous Cell Carcinoma of Head and Neck
No biomarker
Squamous Cell Carcinoma of Head and Neck
LYT-200
Sensitive: B - Late Trials
Businesswire - 2 weeks (New B)
LYT-200
Sensitive
:
B
Businesswire - 2wk
LYT-200
Sensitive: B - Late Trials
Businesswire - 2 weeks
LYT-200
Sensitive
:
B
Businesswire - 2 weeks - (New B)
No biomarker
Multiple Myeloma
No biomarker
Multiple Myeloma
idecabtagene vicleucel
Sensitive: A1 - Approval
Bristol-Myers Squibb Press Release - 3 weeks (New A1)
idecabtagene vicleucel
Sensitive
:
A1
Bristol-Myers Squibb Press Release - 3wk
idecabtagene vicleucel
Sensitive: A1 - Approval
Bristol-Myers Squibb Press Release - 3 weeks
idecabtagene vicleucel
Sensitive
:
A1
Bristol-Myers Squibb Press Release - 3 weeks - (New A1)
BRCA mutation
HER2 Negative Breast Cancer
BRCA mutation
HER2 Negative Breast Cancer
rivoceranib + fluzoparib
Sensitive: B - Late Trials
NAVLIN DAILY - 3 weeks (New B)
rivoceranib + fluzoparib
Sensitive
:
B
NAVLIN DAILY - 3wk
rivoceranib + fluzoparib
Sensitive: B - Late Trials
NAVLIN DAILY - 3 weeks
rivoceranib + fluzoparib
Sensitive
:
B
NAVLIN DAILY - 3 weeks - (New B)
MSI-H/dMMR
Endometrial Cancer
MSI-H/dMMR
Endometrial Cancer
sintilimab + fruquintinib
Sensitive: B - Late Trials
GlobeNewswire - 3 weeks (New B)
sintilimab + fruquintinib
Sensitive
:
B
GlobeNewswire - 3wk
sintilimab + fruquintinib
Sensitive: B - Late Trials
GlobeNewswire - 3 weeks
sintilimab + fruquintinib
Sensitive
:
B
GlobeNewswire - 3 weeks - (New B)
No biomarker
Glioblastoma
No biomarker
Glioblastoma
NOX-A12
Sensitive: B - Late Trials
Businesswire - 3 weeks (New B)
NOX-A12
Sensitive
:
B
Businesswire - 3wk
NOX-A12
Sensitive: B - Late Trials
Businesswire - 3 weeks
NOX-A12
Sensitive
:
B
Businesswire - 3 weeks - (New B)
No biomarker
Small Cell Lung Cancer
No biomarker
Small Cell Lung Cancer
PT217
Sensitive: B - Late Trials
PRNewswire - 3 weeks (New B)
PT217
Sensitive
:
B
PRNewswire - 3wk
PT217
Sensitive: B - Late Trials
PRNewswire - 3 weeks
PT217
Sensitive
:
B
PRNewswire - 3 weeks - (New B)
HER-2 expression
Solid Tumor
HER-2 expression
Solid Tumor
fam-trastuzumab deruxtecan-nxki
Sensitive: A1 - Approval
AstraZeneca Press Release - 3 weeks (New A1)
fam-trastuzumab deruxtecan-nxki
Sensitive
:
A1
AstraZeneca Press Release - 3wk
fam-trastuzumab deruxtecan-nxki
Sensitive: A1 - Approval
AstraZeneca Press Release - 3 weeks
fam-trastuzumab deruxtecan-nxki
Sensitive
:
A1
AstraZeneca Press Release - 3 weeks - (New A1)
EGFR exon 20 insertion
Non Small Cell Lung Cancer
EGFR exon 20 insertion
Non Small Cell Lung Cancer
DZD9008
Sensitive: A1 - Approval
PRNewswire - 3 weeks (New B)
DZD9008
Sensitive
:
A1
PRNewswire - 3wk
DZD9008
Sensitive: A1 - Approval
PRNewswire - 3 weeks
DZD9008
Sensitive
:
A1
PRNewswire - 3 weeks - (New B)
No biomarker
Marginal Zone Lymphoma
No biomarker
Marginal Zone Lymphoma
zanubrutinib
Sensitive: A1 - Approval
zanubrutinib
Sensitive
:
A1
zanubrutinib
Sensitive: A1 - Approval
zanubrutinib
Sensitive
:
A1
No biomarker
Multiple Myeloma
No biomarker
Multiple Myeloma
pomalidomide + elotuzumab
Sensitive: A1 - Approval
pomalidomide + elotuzumab
Sensitive
:
A1
pomalidomide + elotuzumab
Sensitive: A1 - Approval
pomalidomide + elotuzumab
Sensitive
:
A1
No biomarker
Diffuse Large B Cell Lymphoma
No biomarker
Diffuse Large B Cell Lymphoma
lisocabtagene maraleucel
Sensitive: A1 - Approval
lisocabtagene maraleucel
Sensitive
:
A1
lisocabtagene maraleucel
Sensitive: A1 - Approval
lisocabtagene maraleucel
Sensitive
:
A1
CD20 positive
Chronic Lymphocytic Leukemia
CD20 positive
Chronic Lymphocytic Leukemia
rituximab-abbs
Sensitive: A1 - Approval
rituximab-abbs
Sensitive
:
A1
rituximab-abbs
Sensitive: A1 - Approval
rituximab-abbs
Sensitive
:
A1
PD-L1 expression
Non Small Cell Lung Cancer
PD-L1 expression
Non Small Cell Lung Cancer
atezolizumab
Sensitive: A1 - Approval
atezolizumab
Sensitive
:
A1
atezolizumab
Sensitive: A1 - Approval
atezolizumab
Sensitive
:
A1
EGFR exon 19 deletion
Non Small Cell Lung Cancer
EGFR exon 19 deletion
Non Small Cell Lung Cancer
afatinib
Sensitive: A1 - Approval
afatinib
Sensitive
:
A1
afatinib
Sensitive: A1 - Approval
afatinib
Sensitive
:
A1
EGFR exon 19 deletion
Non Small Cell Lung Cancer
EGFR exon 19 deletion
Non Small Cell Lung Cancer
osimertinib
Sensitive: A1 - Approval
osimertinib
Sensitive
:
A1
osimertinib
Sensitive: A1 - Approval
osimertinib
Sensitive
:
A1
No biomarker
Non Small Cell Lung Cancer
No biomarker
Non Small Cell Lung Cancer
ramucirumab
Sensitive: A1 - Approval
ramucirumab
Sensitive
:
A1
ramucirumab
Sensitive: A1 - Approval
ramucirumab
Sensitive
:
A1
MSI-H/dMMR
Small Intestinal Carcinoma
MSI-H/dMMR
Small Intestinal Carcinoma
pembrolizumab
Sensitive: A1 - Approval
pembrolizumab
Sensitive
:
A1
pembrolizumab
Sensitive: A1 - Approval
pembrolizumab
Sensitive
:
A1
ALK positive
Non Small Cell Lung Cancer
ALK positive
Non Small Cell Lung Cancer
lorlatinib
Sensitive: A1 - Approval
lorlatinib
Sensitive
:
A1
lorlatinib
Sensitive: A1 - Approval
lorlatinib
Sensitive
:
A1
EGFR exon 19 deletion
Non Small Cell Lung Cancer
EGFR exon 19 deletion
Non Small Cell Lung Cancer
gefitinib
Sensitive: A1 - Approval
gefitinib
Sensitive
:
A1
gefitinib
Sensitive: A1 - Approval
gefitinib
Sensitive
:
A1
PD-L1 expression
Triple Negative Breast Cancer
PD-L1 expression
Triple Negative Breast Cancer
atezolizumab
Sensitive: A1 - Approval
atezolizumab
Sensitive
:
A1
atezolizumab
Sensitive: A1 - Approval
atezolizumab
Sensitive
:
A1
EGFR L858R
Non Small Cell Lung Cancer
EGFR L858R
Non Small Cell Lung Cancer
afatinib
Sensitive: A1 - Approval
afatinib
Sensitive
:
A1
afatinib
Sensitive: A1 - Approval
afatinib
Sensitive
:
A1
EGFR T790M
Non Small Cell Lung Cancer
EGFR T790M
Non Small Cell Lung Cancer
osimertinib
Sensitive: A1 - Approval
osimertinib
Sensitive
:
A1
osimertinib
Sensitive: A1 - Approval
osimertinib
Sensitive
:
A1
No biomarker
Non Small Cell Lung Cancer
No biomarker
Non Small Cell Lung Cancer
durvalumab
Sensitive: A1 - Approval
durvalumab
Sensitive
:
A1
durvalumab
Sensitive: A1 - Approval
durvalumab
Sensitive
:
A1
HER-2 positive
HER2 Positive Breast Cancer
HER-2 positive
HER2 Positive Breast Cancer
trastuzumab + tucatinib
Sensitive: A1 - Approval
trastuzumab + tucatinib
Sensitive
:
A1
trastuzumab + tucatinib
Sensitive: A1 - Approval
trastuzumab + tucatinib
Sensitive
:
A1
HER-2 positive
HER2 Positive Breast Cancer
HER-2 positive
HER2 Positive Breast Cancer
trastuzumab + pertuzumab
Sensitive: A1 - Approval
trastuzumab + pertuzumab
Sensitive
:
A1
trastuzumab + pertuzumab
Sensitive: A1 - Approval
trastuzumab + pertuzumab
Sensitive
:
A1
KIT positive
Gastrointestinal Stromal Tumor
KIT positive
Gastrointestinal Stromal Tumor
imatinib
Sensitive: A1 - Approval
imatinib
Sensitive
:
A1
imatinib
Sensitive: A1 - Approval
imatinib
Sensitive
:
A1
HER-2 positive
HER2 Positive Breast Cancer
HER-2 positive
HER2 Positive Breast Cancer
margetuximab
Sensitive: A1 - Approval
margetuximab
Sensitive
:
A1
margetuximab
Sensitive: A1 - Approval
margetuximab
Sensitive
:
A1
No biomarker
Renal Cell Carcinoma
No biomarker
Renal Cell Carcinoma
nivolumab + cabozantinib tablet
Sensitive: A1 - Approval
nivolumab + cabozantinib tablet
Sensitive
:
A1
nivolumab + cabozantinib tablet
Sensitive: A1 - Approval
nivolumab + cabozantinib tablet
Sensitive
:
A1
No biomarker
Malignant Pleural Mesothelioma
No biomarker
Malignant Pleural Mesothelioma
nivolumab + ipilimumab
Sensitive: A1 - Approval
nivolumab + ipilimumab
Sensitive
:
A1
nivolumab + ipilimumab
Sensitive: A1 - Approval
nivolumab + ipilimumab
Sensitive
:
A1
PD-L1 expression
Non Small Cell Lung Cancer
PD-L1 expression
Non Small Cell Lung Cancer
pembrolizumab
Sensitive: A1 - Approval
pembrolizumab
Sensitive
:
A1
pembrolizumab
Sensitive: A1 - Approval
pembrolizumab
Sensitive
:
A1
ALK fusion
Non Small Cell Lung Cancer
ALK fusion
Non Small Cell Lung Cancer
brigatinib
Sensitive: A1 - Approval
brigatinib
Sensitive
:
A1
brigatinib
Sensitive: A1 - Approval
brigatinib
Sensitive
:
A1
HER-2 positive
Gastroesophageal Junction Adenocarcinoma
HER-2 positive
Gastroesophageal Junction Adenocarcinoma
trastuzumab
Sensitive: A1 - Approval
trastuzumab
Sensitive
:
A1
trastuzumab
Sensitive: A1 - Approval
trastuzumab
Sensitive
:
A1
No biomarker
Follicular Lymphoma
No biomarker
Follicular Lymphoma
axicabtagene ciloleucel
Sensitive: A1 - Approval
axicabtagene ciloleucel
Sensitive
:
A1
axicabtagene ciloleucel
Sensitive: A1 - Approval
axicabtagene ciloleucel
Sensitive
:
A1
No biomarker
Diffuse Large B Cell Lymphoma
No biomarker
Diffuse Large B Cell Lymphoma
axicabtagene ciloleucel
Sensitive: A1 - Approval
axicabtagene ciloleucel
Sensitive
:
A1
axicabtagene ciloleucel
Sensitive: A1 - Approval
axicabtagene ciloleucel
Sensitive
:
A1
No biomarker
Mediastinal B Cell Lymphoma
No biomarker
Mediastinal B Cell Lymphoma
axicabtagene ciloleucel
Sensitive: A1 - Approval
axicabtagene ciloleucel
Sensitive
:
A1
axicabtagene ciloleucel
Sensitive: A1 - Approval
axicabtagene ciloleucel
Sensitive
:
A1
PDGFRA D842V
Gastrointestinal Stromal Tumor
PDGFRA D842V
Gastrointestinal Stromal Tumor
avapritinib
Sensitive: A1 - Approval
avapritinib
Sensitive
:
A1
avapritinib
Sensitive: A1 - Approval
avapritinib
Sensitive
:
A1
No biomarker
Gastroesophageal Junction Adenocarcinoma
No biomarker
Gastroesophageal Junction Adenocarcinoma
nivolumab
Sensitive: A1 - Approval
nivolumab
Sensitive
:
A1
nivolumab
Sensitive: A1 - Approval
nivolumab
Sensitive
:
A1
No biomarker
Esophageal Cancer
No biomarker
Esophageal Cancer
nivolumab
Sensitive: A1 - Approval
nivolumab
Sensitive
:
A1
nivolumab
Sensitive: A1 - Approval
nivolumab
Sensitive
:
A1
No biomarker
Esophageal Squamous Cell Carcinoma
No biomarker
Esophageal Squamous Cell Carcinoma
nivolumab
Sensitive: A1 - Approval
nivolumab
Sensitive
:
A1
nivolumab
Sensitive: A1 - Approval
nivolumab
Sensitive
:
A1
No biomarker
Fallopian Tube Cancer
No biomarker
Fallopian Tube Cancer
niraparib
Sensitive: A1 - Approval
niraparib
Sensitive
:
A1
niraparib
Sensitive: A1 - Approval
niraparib
Sensitive
:
A1
^
^
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login